Grifols


Plasma supply normalisation taking longer than expected

04/12/21 -"The recent surge of the more-contagious Omicron variant could result in delayed recovery for plasma supplies. Remember, with various preliminary studies signalling limited protection from currently ..."

Pages
61
Language
English
Published on
04/12/21
You may also be interested by these reports :
08/05/24
Sandoz is moving ahead well with two crucial aspects of its medium-term sales and profitability goals: 1/ a strong performance from Biosimilars and ...

07/05/24
Q1 sales missed the consensus estimates, although the CER growth was largely in line with the firm’s full-year outlook. Biosimilars were the main ...

03/05/24
Genmab’s Q1 sales exceeded expectations, although profitability fell somewhat short. This robust performance was led by strong growth across all the ...

03/05/24
We have rolled forward our model to include a new forecast year (2026) which will also see continued healthy top-line growth and profitability ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO